1. Case Studies

3. This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States, and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

4. Merkel Cell Carcinoma: Introduction

5. Case: Ron

6. MCC: Clinical Presentation

7. Ron: PET Scan and Surgery

8. Ron: 1 Month Post Surgery

9. Ron: Initiation of Immunotherapy

10. Ron: Neurologic AEs

11. Immune-Mediated AEs Associated With Checkpoint Inhibitors

12. Ron: Follow-Up Clinical Presentation

13. Case: Phillipe

14. Phillipe: Regional Lymph Node Relapse

15. Phillipe: Metastatic Disease

16. Reported Recurrence Rates for MCC

17. Phillipe: Initiation of Chemotherapy

18. CT Scans Prior to and Following Chemotherapy

19. Relapse and Retreatment

20. Enrollment in Clinical Trial: Baseline CT Scan

21. First Evaluation: CT Scan

22. Comparative PET Scans

23. PET Scan >1 Year After Discontinuing Avelumab

24. Unanswered Questions Regarding the Management of MCC

25. Immune Checkpoint Inhibitors: Mechanism of Action

26. Pembrolizumab: Key Study Highlights

27. Avelumab: Key Study Highlights and Updates

28. Patient Selection: Weighing the Risks and Benefits

29. Concluding Remarks and Future Directions

30. Abbreviations